Bachem recognized as a winner at the Swiss Biotech Success Stories Awards 2021

June 08, 2021

Bachem is excited to announce that the company has been recognized as one of the five winners of the Swiss Biotech Success Stories Awards 2021.

The awards, bestowed by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland.

Bachem is a world leader in the manufacturing of peptides and is expanding into oligonucleotides – both are highly complex drug substances that are increasingly used in modern medicine. The company was founded in Switzerland and has sites in Vionnaz and Bubendorf, as well as sites in the UK, the US and an office in Japan.

“I am happy that Bachem has won a Swiss Biotech Success Stories Award. Within fifty years, we have grown from a small company of two people to a leading provider for the world’s biopharmaceutical industry. This award is a testament to the team of talented and dedicated people that are the foundation of Bachem’s long-term success. I would like to thank the Swiss Biotech Association for this recognition.

We are proud of our strong Swiss heritage as we are of the strong global impact we can make for our customers and ultimately patients worldwide.

At Bachem, we take a long-term approach and continue to see broad-based growth, both in terms of products and geography. Despite the challenges of the ongoing COVID-19 pandemic, we continue to build new production capabilities and hire people across all our sites.”

Thomas Meier

CEO, Bachem AG

“The tag for our initiative is Success Stories, but what we really mean is Value! Bachem is an entrepreneurial story that consistently created value for the last 50 years in Switzerland and abroad. Like with the current laureates and the one to come, it is important to celebrate valuable achievements within the life sciences ecosystem but it is also essential to share it with the public to educate, and the young generations as a palatable path forward for their future.”

Luca Bolliger

President of the Jury, Swiss Biotech Success Stories

Success categories

Bachem was chosen as a winner due to a number of success categories, including:

  • Completed achievement with lasting impact
  • Creation of jobs in Switzerland
  • Enabler for the biotech industry
  • Involvement of one or more Swiss citizens
  • Product approval and sustainable revenues
  • Swiss-based company / institution
  • Swissness: Think global, made in Switzerland

impressions from swiss biotech day 2021

The Swiss Biotech Day 2021 took place on Tuesday, September 7, 2021.

It was a great event, where senior experts and delegations from the life science industry from across Europe came together.

The award ceremony for the Swiss Biotech Success Stories took place during this event. Bachem is grateful and proud that its Bachem Success Story received an award for its sustainable contributions to the Swiss biotech industry.

Team Bachem gets the award at the Swisss Biotech Day 2021 in Basel!

It was also nice to have Thomas Meier participate in a highly interesting panel discussion with other colleagues from the biochemical industry on the state of pharmaceutical production in Switzerland.

Our CEO Thomas Meier participates in the panel discussion at Swiss Biotech Day 2021

About the Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.  The company is listed on the SIX Swiss Exchange.

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Infographic Bachem Smart Factory
Figure 1 - Bachem's smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

Bachem Amino Acid Loading Unit
Figure 2 - Robot's roles in the SPPS

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

watch our video to learn more about our digital transformation

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Automation Pyramid
Figure 3 - The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of "Tides"

Watch the full presentation exclusively on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_section]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_post_content]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Infographic Bachem Smart Factory
Figure 1 - Bachem's smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

Bachem Amino Acid Loading Unit
Figure 2 - Robot's roles in the SPPS

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

watch our video to learn more about our digital transformation

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Automation Pyramid
Figure 3 - The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of "Tides"

Watch the full presentation exclusively on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]
[/et_pb_row]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 - Bachem's smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 - The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of "Tides"

Watch the full presentation exclusively on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 - Bachem's smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 - The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of "Tides"

Watch the full presentation on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 - Bachem's smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 - The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Watch the full presentation on Bachem360.
Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]
[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 - Bachem's smart production of peptides via SPPS
Figure 1 - Bachem's smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 - The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]
[/et_pb_column]

test theme builder local clear 256mb

[/et_pb_row]

Bachem is excited to announce that the company has been recognized as one of the five winners of the Swiss Biotech Success Stories Awards 2021.

The awards, bestowed by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland.

Bachem is a world leader in the manufacturing of peptides and is expanding into oligonucleotides – both are highly complex drug substances that are increasingly used in modern medicine. The company was founded in Switzerland and has sites in Vionnaz and Bubendorf, as well as sites in the UK, the US and an office in Japan.

“I am happy that Bachem has won a Swiss Biotech Success Stories Award. Within fifty years, we have grown from a small company of two people to a leading provider for the world’s biopharmaceutical industry. This award is a testament to the team of talented and dedicated people that are the foundation of Bachem’s long-term success. I would like to thank the Swiss Biotech Association for this recognition.

We are proud of our strong Swiss heritage as we are of the strong global impact we can make for our customers and ultimately patients worldwide.

At Bachem, we take a long-term approach and continue to see broad-based growth, both in terms of products and geography. Despite the challenges of the ongoing COVID-19 pandemic, we continue to build new production capabilities and hire people across all our sites.”

Thomas Meier

CEO, Bachem AG

“The tag for our initiative is Success Stories, but what we really mean is Value! Bachem is an entrepreneurial story that consistently created value for the last 50 years in Switzerland and abroad. Like with the current laureates and the one to come, it is important to celebrate valuable achievements within the life sciences ecosystem but it is also essential to share it with the public to educate, and the young generations as a palatable path forward for their future.”

Luca Bolliger

President of the Jury, Swiss Biotech Success Stories

Success categories

Bachem was chosen as a winner due to a number of success categories, including:

  • Completed achievement with lasting impact
  • Creation of jobs in Switzerland
  • Enabler for the biotech industry
  • Involvement of one or more Swiss citizens
  • Product approval and sustainable revenues
  • Swiss-based company / institution
  • Swissness: Think global, made in Switzerland

impressions from swiss biotech day 2021

The Swiss Biotech Day 2021 took place on Tuesday, September 7, 2021.

It was a great event, where senior experts and delegations from the life science industry from across Europe came together.

The award ceremony for the Swiss Biotech Success Stories took place during this event. Bachem is grateful and proud that its Bachem Success Story received an award for its sustainable contributions to the Swiss biotech industry.

Team Bachem gets the award at the Swisss Biotech Day 2021 in Basel!

It was also nice to have Thomas Meier participate in a highly interesting panel discussion with other colleagues from the biochemical industry on the state of pharmaceutical production in Switzerland.

Our CEO Thomas Meier participates in the panel discussion at Swiss Biotech Day 2021

About the Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.  The company is listed on the SIX Swiss Exchange.

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Infographic Bachem Smart Factory
Figure 1 – Bachem’s smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

Bachem Amino Acid Loading Unit
Figure 2 – Robot’s roles in the SPPS

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

watch our video to learn more about our digital transformation

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Automation Pyramid
Figure 3 – The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of “Tides”

Watch the full presentation exclusively on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]
[/et_pb_row]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 – Bachem’s smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 – The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of “Tides”

Watch the full presentation exclusively on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 – Bachem’s smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 – The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Implementation of Industry 4.0 concepts for the manufacturing of “Tides”

Watch the full presentation on Bachem360.

Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 – Bachem’s smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 – The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

Watch the full presentation on Bachem360.
Visit the CMC development section inside the live area.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]
[/et_pb_column]

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. Within this concept, a “smart factory” is characterized by machines which are interconnected, and interoperable, and can process data autonomously. Such “smart factories” require only limited human decision-making or intervention and are therefore sometimes referred to as “intelligent automation.”

Innovation and operational excellence are two important pillars of Bachem’s success. Thus, to keep technological leadership and high-quality services, it was essential to start our digital transformation and to enter the Industry 4.0 area. This will benefit our customers, as we will be able to increase our capacity with a more agile and flexible production, simplify and improve our GMP documentation, and provide a safe, reliable, and scalable manufacturing process delivering consistently high quality API.

Why are we automating and digitalizing SPPS at Bachem?

Optimizing production is crucial to us to help and support our customers in their drug development and manufacturing processes. We have started our journey to Industry 4.0 by automating and digitalizing one of our core business processes, the solid phase peptide synthesis (SPPS) (Figure 1).

Figure 1 – Bachem’s smart production of peptides via SPPS
Figure 1 – Bachem’s smart production of peptides via SPPS

We have automated our SPPS process so that operations can be carried out with minimal human intervention, thus improving the reliability of the process, reproducibility of results and safety, while significantly increasing the cost-effectiveness of operations. Thanks to automation, we are able to optimize equipment utilization and reduce operating times and personnel time down to a fraction. This reduction enables a higher capacity, efficiency and agility of production and brings more flexibility to take on new projects. Bachem has also invested in digitalization of the production process so that documentation can be conducted in a paper-free way. Furthermore, we can attain improved first-time-right (FTR) rates, data analytics by implementing a plant information (PI) system, and higher data safety and integrity.

Our process innovations

As first steps towards our “smart factory”, we have introduced some major innovations. The first Bachem robot-operator, BALU, was designed and programmed to support commercial scale of SPPS. BALU handles the containers with the amino acid powders and is able to perform the powder transfer into the activator vessels for our 150L SPPS reactors. And the robot does so without the involvement of an operator. BALU can perform other critical tasks, such as cleaning the amino acid transfer port to prevent cross-contamination. A barcode scanner that reads the labels placed on the amino acid containers ensures correct handling.

watch our video to learn more about BALU

Another innovative feature of this new fully automated SPPS process is Process Analytical Technology (PAT), which performs inline analytics after key steps. PAT removes the need for manual In-Process Controls (IPC) and provides a better control of Critical Process Parameters (CPP). Additionally, this automated process enables data recording and analytics as well as paper-free cGMP documentation. Implementing PAT to our process control decreases human contributions and cost of goods. Indeed, manual tasks are no longer required and frees resources for other tasks and projects. Furthermore, PAT leads to a higher reproducibility with minimized chemical side reactions. Ultimately, we utilize our assets more efficiently and streamline our production scheduling for a higher capacity and flexibility.

Our digitalization strategy

Our digitalization of the SPPS process was tackled in the following way: the control system of the production floor (Levels 1 and 2 of the Automation Pyramid, see Figure 2) has been integrated with the Manufacturing Execution System (MES, Level 3 in Figure 2). The MES has three critical tasks:

  • lead the process control system by defining the sequence of operations that have to be performed (as written in the MES recipe, also called Master Batch Record, MBR)
  • record all events, process values, alarms, as they happen during the process, and finally generate the electronic Batch Report, eBR
  • manage equipment without the need of physical logbooks.

MES documentation is thus completely paperless while fully GMP compliant!

Full digitalization is reached by connecting the MES to our ERP system, SAP (Level 4 in Figure 2). Executions of process orders, automatic take-out and stock creations, material flow and inventory control are in this way also fully automated and paperless. Finally, our digitalization strategy includes logging in real time and long-term archiving of data on a Historian platform. This PI system allows for real-time and remote monitoring of the factory floor and easy access to data for trending and batch-to-batch comparisons. This provides the basis for future predictive and prescriptive data analytics.

Figure 3 – The automation pyramid

Bachem will embrace a “smart” future together with our customers

Bachem as a CDMO has implemented a new level of automation and digitalization to fulfill the predicted rise in demand of capacity and compliance. We boosted our processes efficiency regarding time, cost, supply and distribution. Entering industry 4.0 and developing our “smart factory” represents a big step forward for our customers in ensuring swifter interaction and more flexibility in manufacturing and in documentation sharing.

Digitalization and automation initiatives are quickly growing, and, in the coming years, thanks to our experiences in SPPS, a growing number of processes will be transformed this way. With these innovations, we keep our technological leadership and set a high industry standard for the best interests of our customers!

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

[/et_pb_column]
[/et_pb_column]

test theme builder local clear 256mb

[/et_pb_row]
[/et_pb_column]

Bachem is excited to announce that the company has been recognized as one of the five winners of the Swiss Biotech Success Stories Awards 2021.

The awards, bestowed by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland.

Bachem is a world leader in the manufacturing of peptides and is expanding into oligonucleotides – both are highly complex drug substances that are increasingly used in modern medicine. The company was founded in Switzerland and has sites in Vionnaz and Bubendorf, as well as sites in the UK, the US and an office in Japan.

“I am happy that Bachem has won a Swiss Biotech Success Stories Award. Within fifty years, we have grown from a small company of two people to a leading provider for the world’s biopharmaceutical industry. This award is a testament to the team of talented and dedicated people that are the foundation of Bachem’s long-term success. I would like to thank the Swiss Biotech Association for this recognition.

We are proud of our strong Swiss heritage as we are of the strong global impact we can make for our customers and ultimately patients worldwide.

At Bachem, we take a long-term approach and continue to see broad-based growth, both in terms of products and geography. Despite the challenges of the ongoing COVID-19 pandemic, we continue to build new production capabilities and hire people across all our sites.”

Thomas Meier

CEO, Bachem AG

“The tag for our initiative is Success Stories, but what we really mean is Value! Bachem is an entrepreneurial story that consistently created value for the last 50 years in Switzerland and abroad. Like with the current laureates and the one to come, it is important to celebrate valuable achievements within the life sciences ecosystem but it is also essential to share it with the public to educate, and the young generations as a palatable path forward for their future.”

Luca Bolliger

President of the Jury, Swiss Biotech Success Stories

Success categories

Bachem was chosen as a winner due to a number of success categories, including:

  • Completed achievement with lasting impact
  • Creation of jobs in Switzerland
  • Enabler for the biotech industry
  • Involvement of one or more Swiss citizens
  • Product approval and sustainable revenues
  • Swiss-based company / institution
  • Swissness: Think global, made in Switzerland

impressions from swiss biotech day 2021

The Swiss Biotech Day 2021 took place on Tuesday, September 7, 2021.

It was a great event, where senior experts and delegations from the life science industry from across Europe came together.

The award ceremony for the Swiss Biotech Success Stories took place during this event. Bachem is grateful and proud that its Bachem Success Story received an award for its sustainable contributions to the Swiss biotech industry.

Team Bachem gets the award at the Swisss Biotech Day 2021 in Basel!

It was also nice to have Thomas Meier participate in a highly interesting panel discussion with other colleagues from the biochemical industry on the state of pharmaceutical production in Switzerland.

Our CEO Thomas Meier participates in the panel discussion at Swiss Biotech Day 2021

About the Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.  The company is listed on the SIX Swiss Exchange.

Subscribe to our newsletter

  • Hidden
    :
  • This field is for validation purposes and should be left unchanged.

[/et_pb_section]
[/et_pb_column]
[/et_pb_column]